|
|
|
|
Дата |
|---|
| 25.09.2026 |
| 24.09.2026 |
| 23.09.2026 |
| 22.09.2026 |
| 21.09.2026 |
| 18.09.2026 |
| 17.09.2026 |
| 16.09.2026 |
| 15.09.2026 |
| 14.09.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
9.00
|
11.00
|
10.81
|
10.39
|
10.87
|
10.46
|
|
|
3 352 782.34
|
4 485.00
|
|
9.00
|
11.83
|
10.60
|
10.1601
|
10.86
|
10.76
|
|
|
3 645 110.69
|
5 395.00
|
|
8.03
|
11.83
|
10.89
|
10.13
|
10.93
|
10.77
|
|
|
5 706 199.28
|
5 826.00
|
|
10.60
|
11.83
|
11.02
|
10.64
|
11.2755
|
10.86
|
|
|
4 475 168.63
|
5 428.00
|
|
10.81
|
11.83
|
11.06
|
10.78
|
11.28
|
10.90
|
|
|
5 972 931.62
|
7 185.00
|
|
8.03
|
11.83
|
11.21
|
10.51
|
11.21
|
10.92
|
|
|
20 006 047.96
|
6 821.00
|
|
8.03
|
11.83
|
11.57
|
11.13
|
11.7316
|
11.32
|
|
|
6 202 509.80
|
7 435.00
|
|
8.03
|
12.45
|
12.06
|
11.35
|
12.155
|
11.40
|
|
|
7 130 034.69
|
7 506.00
|
|
11.90
|
12.45
|
13.10
|
12.05
|
13.11
|
12.08
|
|
|
4 940 076.27
|
5 641.00
|
|
12.36
|
13.75
|
13.08
|
12.66
|
13.45
|
13.15
|
|
|
4 294 310.45
|
5 281.00
|
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded by leading experts in psychiatry and neuroscience, dedicated to addressing significant unmet medical needs in central nervous system (CNS) disorders. The firm’s proprietary discovery platform-leveraging optogenetics, spatial transcriptomics (STARmap) and circuit-based neuroscience-aims to identify and modulate the specific neural circuits underlying diseases. Their lead candidate, ML-007C-MA (an M/M muscarinic agonist co-formulated with a peripherally acting anticholinergic), is currently in Phase 2 development for indications including schizophrenia and Alzheimer’s disease psychosis.
The company is headquartered in Redwood City, California, and recently completed a large Series D financing of US $372.5 million to advance its pipeline.
Показать все Скрыть